• Dépistage, diagnostic, pronostic

  • Découverte de technologies et de biomarqueurs

  • Voies aérodigestives supérieures

Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma

A partir de sections d'échantillons biopsiques prélevés sur 72 patients atteints d'un carcinome épidermoïde de l'oropharynx, cette étude met en évidence l'intérêt d'une méthode automatisée pour quantifier par immunofluorescence les interactions spatiales entre les lymphocytes T et les cellules exprimant PD-L1, et établir un pronostic

Background : Fulfilling the promise of cancer immunotherapy requires novel predictive biomarkers to characterise the host immune microenvironment. Deciphering the complexity of immune cell interactions requires an automated multiplex approach to histological analysis of tumour sections. We tested a new automatic approach to select tissue and quantify the frequencies of cell-cell spatial interactions occurring in the PD1/PD-L1 pathway, hypothesised to reflect immune escape in oropharyngeal squamous cell carcinoma (OPSCC).

Methods : Single sections of diagnostic biopsies from 72 OPSCC patients were stained using multiplex immunofluorescence (CD8, PD1, PD-L1, CD68). Following multispectral scanning and automated regions-of-interest selection, the Hypothesised Interaction Distribution (HID) method quantified spatial proximity between cells. Method applicability was tested by investigating the prognostic significance of co-localised cells (within 30

μm) in patients stratified by HPV status.

Results

:

High frequencies of proximal CD8+ and PD-L1+ (HR 2.95, p

= 0.025) and PD1+ and PD-L1+ (HR 2.64, p = 0.042) cells were prognostic for poor overall survival in patients with HPV negative OPSCC (n = 31).

Conclusion : The HID method can quantify spatial interactions considered to reflect immune escape and generate prognostic information in OPSCC. The new automated approach is ready to test in additional cohorts and its applicability should be explored in research and clinical studies.

British Journal of Cancer , résumé, 2019

Voir le bulletin